Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the antispasmodics drugs market grown in recent years?

The market size of antispasmodics drugs has shown rapid growth in the past few years. It is projected to expand from $13.76 billion in 2024 to $15.07 billion in 2025, boasting a compound annual growth rate (CAGR) of 9.5%. This upward trend in the historically can be linked to an increase in the incidence of spasmodic conditions, medical research advancements, an increasing elderly population, lifestyle changes, and advancements in diagnosis.

How is the antispasmodics drugs market size expected to evolve during the forecast period?

The size of the antispasmodics drugs market is anticipated to experience robust expansion in the upcoming years, reaching a valuation of $21.91 billion by 2029, with a compound annual growth rate (CAGR) of 9.8%. The growth anticipated during the forecast era is due to factors such as increased expenditure on healthcare, tailored medicine, global population increase, emerging markets, as well as clinical trials and research. The forecast period will witness a variety of key trends including the widening implications for antispasmodics, development of healthcare infrastructure, advancements in drug development, rising awareness and diagnosis, and a preference for non-invasive treatment alternatives.

Get your antispasmodics drugs market report here!

https://www.thebusinessresearchcompany.com/report/antispasmodics-drugs-global-market-report

Which key drivers are propelling the antispasmodics drugs market’s growth?

As the population of senior citizens surges, it is predicted to fuel the expansion of the antispasmodic drug market. Individuals aged 65 and above are categorized as older adults who are prone to numerous physical and mental health conditions. Antispasmodic medications are beneficial for this demographic in managing symptoms stemming from various disorders which can trigger muscle spasms or cramping, and are also recommended for conditions such as irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), interstitial cystitis, and uterine cramping. As an example, in October 2022, the World Health Organization (WHO), a Switzerland-based institution that oversees global public health, reported that the international segment of the population aged 60 and above will escalate to 1.4 billion by 2030. The global count of people aged 60 and beyond is anticipated to double by 2050, marking 2.1 billion. The population aged 80 and beyond is foreseen to see a considerable rise by 2050, totalling 426 million. Hence, a surge in the population of the elderly will act as a catalyst for the growth of the antispasmodic drug market.

What are the market segments in the antispasmodics drugs industry?

The antispasmodics drugs market covered in this report is segmented –

1) By Drug: Dicyclomine Hydrochloride, Loperamide Hydrochloride, Other Drugs

2) By Indication: Irritable Bowel Syndrome, Stomach Cramps, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Modes Of Administrations

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Dicyclomine Hydrochloride: Oral Tablets, Injectable Formulations

2) By Loperamide Hydrochloride: Oral Tablets, Liquid Formulations

3) By Other Drugs: Hyoscine Butylbromide (Scopolamine), Peppermint Oil, Atropine, Other Antispasmodics

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9414&type=smp

Which leading companies are shaping the growth of the antispasmodics drugs market?

Major companies operating in the antispasmodics drugs market include Daiichi Sankyo Company Limited, Fresenius Kabi AG, Hikma Pharmaceuticals plc, Johnson & Johnson Services Inc., Pfizer Inc., Shanghai Fosun Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Akorn Inc., Aurobindo Pharma Limited, Lannett Company Inc., Nexus Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Blue Cross Laboratories Pvt. Ltd., Dr. Reddy’s Laboratories Ltd., Lexicare Pharma Pvt. Ltd., Solitaire Pharmacia Private Limited, Strides Pharma Science Limited, Wellona Pharma Private Limited, SunGen Pharma LLC, GlaxoSmithKline plc, Novartis AG, Sanofi SA, AstraZeneca plc, Merck & Co. Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Endo Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Lupin Ltd.

What key trends are currently impacting the antispasmodics drugs market’s development?

The trend of product innovation is crucial for gaining traction in the antispasmodic drugs market. Key players in this market are zeroing in on the creation of cutting-edge solutions to solidify their market standing. For example, Ardelyx Inc., a biopharmaceutical enterprise based in the US, unveiled IBSRELA in April 2022. This NHE-3 inhibitor is used to treat people suffering from irritable bowel syndrome with constipation (IBS-C). The product provides a distinct new therapeutic pathway with a fresh method of action and extremely effective outcomes to address constipation and a variety of abdominal symptoms commonly seen in IBS-C patients, as confirmed by Phase 3 clinical trials.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9414

Which geographic areas are influencing the growth of the antispasmodics drugs market?

North America was the largest region in the antispasmodics drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the antispasmodics drugs market report during the forecast period. The regions covered in the antispasmodics drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Cardiovascular Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

Dermatology Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Hematology Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: